NCT Number: NCT00466063
ENTRUST, a 5 Year Surveillance of Children Aged 2 to <6 Years With Transfusional Iron Overload Treated With Deferasirox
This registry will evaluate long-term safety and efficacy of deferasirox in children with transfusional iron overload.
Looking for future studies?
Notify MeKey information
Conditions
Age range
2 year–5 year
Sex eligibility
All sexes
Study type
Observational
Primary location
University of South Alabama Medical Center, Mobile, Alabama, United States
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- History of transfusion-dependent anemia.
- History of iron overload
Exclusion criteria
- Patients with non-transfusional hemosiderosis.
Other protocol-defined inclusion/exclusion criteria may apply.
Treatment and study plan
Primary outcomes
-
Safety - renal and hepatic function monitoring.
Time frame: 5 years
Secondary outcomes
-
Adverse events
Time frame: 5 years
-
Longitudinal ferritin levels
Time frame: 5 years
-
Assessment of auditory and ophthalmologic status
Time frame: 5 years
Sponsors and collaborators
Lead sponsor
Novartis Pharmaceuticals
Industry
Registry information
Official study title
A 5 Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment With Transfusional Hemosiderosis Treated With Deferasirox
Important dates
- Study start
- 2007
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Apr 27, 2007
- Registry last updated
- Dec 29, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Extension Study of Iron Chelation Therapy With Deferasirox in β-thalassemia and Rare Chronic Anemia Patients
NCT00303329
Anemia, Hematologic Diseases
Oakland, California, United States
View Trial DetailsHemoglobin Trends as a Predictor of Outcomes in Critically Ill Patients (The TRENT-ICU Study)
NCT07761832
Anemia, Critical Illness
Querétaro City, Querétaro, Mexico
View Trial DetailsSHIIFT: Small Tubes to Halt Medical ICU/IMU Frequent Transfusions
NCT05750654
Anemia, Hematologic Diseases
Houston, Texas, United States
View Trial DetailsLiberal Transfusion Strategy in Elderly Patients
NCT03369210
Anemia, Hematologic Diseases
Aachen, Germany
View Trial Details